Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial
N. Yanagisawa
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd., Zama, Japan,
Search for more papers by this authorK. Enomoto
Department of Otolaryngology and Sensory Organ Surgery, Osaka University Medical School, Osaka, Japan
Search for more papers by this authorT. Enomoto
Department of Otolaryngology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan
Search for more papers by this authorN. Yanagisawa
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd., Zama, Japan,
Search for more papers by this authorK. Enomoto
Department of Otolaryngology and Sensory Organ Surgery, Osaka University Medical School, Osaka, Japan
Search for more papers by this authorT. Enomoto
Department of Otolaryngology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan
Search for more papers by this authorSummary
Background Probiotic bacteria may be effective in the treatment of allergic inflammation and food allergy, but efficacy and underlying mechanisms remain unclear.
Objective The present study investigated the effects of probiotic strain Bifidobacterium longum BB536 in the treatment of Japanese cedar pollinosis (JCPsis).
Methods In a randomized, double-blind, placebo-controlled trial, 44 JCPsis subjects received BB536 or placebo for 13 weeks during the pollen season. Subjective symptoms and self-care measures were recorded daily and blood samples were taken before and during intervention to measure blood levels of parameters related to JCPsis.
Results BB536 intake was associated with a significant reduction in number of subjects prematurely terminated due to severe symptoms and pollinosis medication (P=0.0057 vs. placebo group). Comparison of subjective symptom scores indicated significant decreases in rhinorrhea, nasal blockage and composite scores in the BB536 group compared with the placebo group. Comparison of medical scores showed marked improvements in all symptoms on BB536 intake. A T-helper type 2 (Th2)-skewed immune response occurring along with pollen dispersion was observed. BB536 significantly suppressed increases in plasma thymus- and activation-regulated chemokine and tended to suppress elevations of Japanese cedar pollen (JCP)-specific IgE.
Conclusion These results suggest the efficacy of BB536 in relieving JCPsis symptoms, probably through the modulation of Th2-skewed immune response.
References
- 1 Enomoto T. Reevaluation of hygiene theory. Arerugi 2004; 53: 465–8.
- 2
Bjorksten B,
Naaber P,
Sepp E,
Mikelsaar M.
The intestinal microflora in allergic Estonian and Swedish 2-year-old children.
Clin Exp Allergy
1999; 108: 342–6.
10.1046/j.1365-2222.1999.00560.x Google Scholar
- 3 Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001; 108: 516–20.
- 4 Guidelines for the Evaluation of Probiotics in Food, Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, London Ontario, Canada, 2002. http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
- 5 Matsuzaki T, Yamazaki R, Hashimoto S, Yokokura T. The effect of oral feeding of Lactobacillus casei strain Shirota on immunoglobulin E production in mice. J Dairy Sci 1998; 81: 48–53.
- 6 Ishida Y, Bandou I, Kanzato H, Yamamoto N. Decrease in ovalbumin specific IgE of mice serum after oral uptake of lactic acid bacteria. Biosci Biochem Biotech 2003; 67: 952–7.
- 7 Fujiwara D, Inoue S, Wakabayashi H, Fujii T. The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance. Int Arch Allergy Immunol 2004; 135: 205–15.
- 8 Kimoto H, Mizumachi K, Okamoto T, Kurisaki J. New Lactococcus strain with immunomodulatory activity: enhancement of Th1-type immune response. Microbiol Immunol 2004; 48: 75–82.
- 9 Ohno H, Tsunemine S, Isa Y, Shimakawa M, Yamamura H. Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen specific immunoglobulin E production in mice. Biol Pharm Bull 2005; 28: 1462–6.
- 10 Hessle C, Hanson LA, Wold AE. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp Immunol 1999; 116: 276–82.
- 11 Niers LE, Timmerman HM, Rijkers GT et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy 2005; 35: 1481–9.
- 12 Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–9.
- 13 Viljanen M, Savilahti E, Haahtela T et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60: 494–500.
- 14 Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol 2004; 5: 152–8.
- 15 Ishida Y, Nakamura F, Kanzato H et al. Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study. J Dairy Sci 2005; 88: 527–33.
- 16 Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol 2005; 16: 433–8.
- 17 Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99: 179–85.
- 18 Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy 2002; 57: 243–6.
- 19 Xiao JZ, Kondo S, Yanagisawa N et al. Effect of Probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season, a randomized, double-blind, placebo-controlled trial. J Invest Allergol Clin Immunol 2006; 16: 86–93.
- 20 Yamazaki S, Machii S, Tsuyuki S, Kawashima T, Ueda K. Immunological responses to monoassociated Bifidobacterium longum and their relations to prevention of invasion. Immunology 1985; 56: 43–56.
- 21 Ishibashi N, Yaeshima T, Hayasawa H. Bifidobacteria: their significance in human intestinal health. Mal J Nutr 1997; 3: 149–59.
- 22 Viljanen M, Pohjavuori E, Haahtela T et al. Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. J Allergy Clin Immunol 2005; 115: 1254–9.
- 23 Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein–Barr virus vector. J Biol Chem 1996; 271: 21514–21.
- 24 Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 1997; 272: 15036–42.
- 25 Locati M, Bonecchi R, Corsi MM. Chemokines and their receptors: roles in specific clinical conditions and measurement in the clinical laboratory. Am J Clin Pathol 2005; 123: S82–95.
- 26 Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129–34.
- 27 Ritter M, Goggel R, Chaudhary N et al. Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation. Biochem Biophys Res Commun 2005; 334: 254–62.
- 28 Okamoto H, Kamatani N. Plasma concentration of TARC/CCL17 is elevated in nonepisodic angioedema associated with eosinophilia. Allergy 2005; 60: 1091–2.
- 29 Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005; 60: 685–8.
- 30 Hijnen D, De Bruin-Weller M, Oosting B et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113: 334–40.
- 31 Sugawara N, Yamashita T, Ote Y, Miura M, Terada N, Kurosawa M. TARC in allergic disease. Allergy 2002; 57: 180–1.
- 32 Stavnezer J. Immunoglobulin class switching. Curr Opin Immunol 1996; 8: 199–205.
- 33 Humbles AA, Lloyd CM, McMillan SJ et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305: 1776–9.
- 34 Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112: 1029–36.
- 35 Pessi T, Sutas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy 2000; 30: 1804–8.
- 36 Laouini D, Alenius H, Bryce P, Oettgen H, Tsitsikov E, Geha RS. IL-10 is critical for Th2 responses in a murine model of allergic dermatitis. J Clin Invest 2000; 112: 1058–66.
- 37 Zemann B, Schwaerzler C, Griot-Wenk M et al. Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF-beta expression and prevents allergy in adult life. J Allergy Clin Immunol 2003; 111: 1069–75.
- 38 Faria AM, Maron R, Ficker SM, Slavin AJ, Spahn T, Weiner HL. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun 2003; 20: 35–45.
Citing Literature
